Alain H Rook Selected Research

Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)

12/2022	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.
1/2022	Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
1/2022	Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol.
1/2022	Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
3/2021	The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
3/2021	The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
1/2021	Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
9/2020	Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab.
1/2019	Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma.
1/2018	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alain H Rook Research Topics

Disease

56	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 12/2022 - 01/2002
21	Mycosis Fungoides 01/2022 - 03/2004
19	Neoplasms (Cancer) 12/2022 - 10/2002
9	Lymphoma (Lymphomas) 01/2022 - 06/2002
6	Pruritus (Itching) 01/2021 - 10/2010
6	Sezary Syndrome (Sezary Erythroderma) 02/2012 - 06/2003
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 06/2002
4	Hematologic Diseases (Blood Diseases) 01/2021 - 04/2008
3	Fever (Fevers) 01/2018 - 10/2002
3	Systemic Scleroderma (Systemic Sclerosis) 10/2009 - 06/2002
3	T-Cell Lymphoma (Lymphoma, T Cell) 07/2008 - 10/2002
2	Atopic Dermatitis (Atopic Eczema) 09/2020 - 05/2015
2	Inflammation (Inflammations) 01/2019 - 09/2015
2	Cellulitis 01/2018 - 12/2003
2	Exfoliative Dermatitis (Erythroderma) 01/2015 - 12/2004
2	Lymphadenopathy 01/2015 - 10/2002
2	Disease Progression 08/2011 - 09/2005
2	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 09/2008 - 03/2005
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 08/2008 - 04/2006
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2008 - 09/2003
2	Skin Diseases (Skin Disease) 04/2008 - 03/2004
2	Arthralgia (Joint Pain) 11/2006 - 10/2002
1	Exanthema (Rash) 01/2022
1	Hemorrhagic Shock 10/2020
1	Neoplasm Metastasis (Metastasis) 10/2020
1	Cytokine Release Syndrome 10/2020
1	Rupture 10/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Bronchopneumonia 01/2018
1	Pulmonary Embolism 01/2018
1	Polymyositis 01/2018
1	Sepsis (Septicemia) 01/2018
1	Progressive Multifocal Leukoencephalopathy 08/2014
1	Skin Neoplasms (Skin Cancer) 03/2014
1	Melanoma (Melanoma, Malignant) 03/2014
1	Hutchinson's Melanotic Freckle (Lentigo Maligna) 03/2014
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 03/2014
1	Basal Cell Neoplasms (Basal Cell Cancer) 03/2014
1	Infections 07/2013

Drug/Important Bio-Agent (IBA)

13	CytokinesIBA 03/2021 - 01/2002
9	Bexarotene (LGD1069)FDA Link 01/2021 - 12/2002
8	Biological ProductsIBA 09/2021 - 01/2002
6	Interleukin-12 (IL 12)IBA 09/2007 - 02/2002
5	InterferonsIBA 10/2015 - 06/2003
4	Histone Deacetylase InhibitorsIBA 12/2022 - 02/2012
4	mogamulizumabIBA 01/2022 - 01/2018
4	Vorinostat FDA Link 01/2022 - 09/2009
4	Interferon-gamma (Interferon, gamma)IBA 01/2020 - 02/2002
4	Interferon-alpha (Interferon Alfa)IBA 10/2015 - 01/2003
4	romidepsin (FK228)FDA Link 01/2015 - 10/2010
4	Interleukin-2 (IL2)IBA 08/2008 - 02/2002
4	denileukin diftitox (Ontak)FDA Link 07/2008 - 06/2002
3	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 09/2003
3	Monoclonal AntibodiesIBA 01/2022 - 08/2014
3	Pharmaceutical PreparationsIBA 01/2020 - 02/2012
3	Carmustine (FIVB)FDA Link 01/2020 - 01/2013
3	Ficusin (Psoralen)IBA 01/2019 - 06/2003
2	Chemokine ReceptorsIBA 03/2021 - 09/2007
2	Brentuximab VedotinIBA 01/2021 - 08/2014
2	AntibodiesIBA 01/2021 - 01/2003
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2017
2	CD40 Ligand (CD40L)IBA 01/2019 - 01/2005
2	resiquimodIBA 09/2015 - 03/2014
2	Imiquimod (Aldara)FDA LinkGeneric 03/2014 - 09/2002
2	Interferon alpha-2 (Roferon-A)FDA Link 09/2011 - 03/2005
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2008 - 01/2005
2	interleukin-21 (interleukin 21)IBA 02/2008 - 02/2008
2	Interleukin-15 (Interleukin 15)IBA 02/2008 - 12/2004
2	Complementary DNA (cDNA)IBA 04/2006 - 06/2003
1	CaspasesIBA 12/2022
1	CCR4 ReceptorsIBA 01/2022
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2022
1	ResveratrolIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	Immune Checkpoint ProteinsIBA 03/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	ChemokinesIBA 01/2021
1	durvalumabIBA 10/2020
1	MEDI9197IBA 10/2020
1	dupilumabIBA 09/2020
1	Isotretinoin (Accutane)FDA LinkGeneric 01/2020
1	pembrolizumabIBA 01/2020
1	CC ChemokinesIBA 01/2018
1	vasectrin IIIIBA 01/2018
1	AT 61IBA 01/2018
1	AntipruriticsIBA 11/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	InterleukinsIBA 05/2015
1	Toll-Like Receptor AgonistsIBA 03/2014
1	Immunoglobulin E (IgE)IBA 07/2013

Therapy/Procedure

35	Therapeutics 01/2022 - 02/2002
6	Photopheresis 05/2017 - 06/2002
5	Immunotherapy 03/2021 - 10/2011
3	Transplantation 01/2020 - 04/2006
3	Immunomodulation 12/2011 - 08/2002
2	Stem Cell Transplantation 09/2015 - 04/2008
2	Drug Therapy (Chemotherapy) 08/2014 - 01/2013
1	Hematopoietic Stem Cell Transplantation 01/2022
1	Radiotherapy 10/2020